FutureMeds named in The Sunday Times 100 for the second consecutive year
- FutureMeds
- Jun 9
- 4 min read
FutureMeds has been named in The Sunday Times 100 for the second year in a row, ranking No. 65 among Britain’s fastest-growing private companies after recording 73.37 percent annual sales growth over three years.
The repeat listing on the Sunday Times 100 is driven by the work behind it: building the infrastructure, teams and oversight needed to make trial delivery more consistent across European countries over time.
“Being named to The Sunday Times 100 for a second year is an important marker, but the wider context is what matters. Clinical research is facing unprecedented pressure from complex protocols and uneven site capacity. We are building our leading position in Europe because our clients need reliable, predictable access to patient populations without adding to their own operational burden. Finally, the data quality decides drug licensing. And that data is being delivered by FutureMeds sites across Europe.”
— Dr Radoslaw Janiak, CEO of FutureMeds
Modernising Europe’s Clinical Infrastructure
The operational pressure on modern clinical trials is growing. Data from the Tufts Center for the Study of Drug Development highlights that since 2005, the industry has seen a 139% increase in procedure quantity and a 600% surge in data points collected per protocol.
For study teams, this complexity translates directly into higher patient burden, strained site staff, and an elevated risk of protocol amendments or patient dropouts. One of the core challenges for the clinical research industry is ensuring that site infrastructure can keep pace with what modern protocols demand.
The operational landscape is also shifting globally, prompting European regulatory bodies and research organisations to focus heavily on modernising trial delivery. While Europe retains its position as a premier hub for medical innovation, recent industry analyses, such as IQVIA’s report for EFPIA, highlight a collective push across the region to optimise site start-up and recruitment timelines to maintain its global competitiveness.
The opportunity in Europe stems from the ongoing coordination required to make complex protocols scalable across diverse healthcare systems. When the right infrastructure is in place, the region's efficiency is evident: markets such as Poland and Spain continue to demonstrate exceptional recruitment speed, particularly in specialised fields like oncology.
“The problem is rarely a lack of good sites. Europe has strong research capabilities, but sponsors must often manage them across different health care systems, with a shortage of dedicated medical/research staff, and without appropriate site-level acceptance of trial technology. That is where FutureMeds can make a practical difference. Our focus is on making that coordination more predictable through dedicated sites, local teams, central oversight and consistent operating standards.”
— Marcin Gondek, Chief Operating Officer
Expanding Infrastructure Across Complementary Models
Founded in 2019 to address site-level delivery challenges, FutureMeds has developed a dual-track approach to expand its pan-European footprint.
The company operates a growing network of dedicated, brick-and-mortar research sites while concurrently scaling its decentralised clinical trial service, FutureMeds @home. To date, FutureMeds has supported more than 32,000 patient enrollments across over 2,300 studies, alongside conducting more than 16,000 home visits.
For clients, this dual infrastructure offers distinct pathways to manage protocol complexity without adding administrative burden. FutureMeds focuses on building consistent operational standards across both models to provide:
Improved Data-Driven Feasibility: Delivering enrollment forecasts derived from localised site data rather than optimistic projections.
Standardised Quality Oversight: Applying unified operating procedures and centralised management to minimise deviations across geographic boundaries.
Flexible Access Options: Providing traditional dedicated site infrastructure for trials requiring intensive on-site investigator oversight, alongside home-visit capabilities to reach patients who face geographic or mobility constraints.
Regulators have increasingly validated the utility of decentralised elements. Recent FDA guidance notes that decentralised components, such as home visits, can reduce participant burden and diversify cohorts.
FutureMeds offers these dual capabilities so sponsors can leverage dedicated physical infrastructure where investigator-led procedures are critical, or utilise the home-visit network where protocol designs allow for remote delivery.
Building a European Clinical Research Platform
FutureMeds’ second consecutive Sunday Times 100 listing coincides with broader recognition for the company’s growth and operating model. Dr Radoslaw Janiak was recently named a regional finalist for the EY Entrepreneur Of The Year UK program, reflecting the development of FutureMeds from a founder-led business launched in 2019 into a more established European clinical research platform.
For institutional partners, this transition demonstrates sustainable, compounded expansion against a significantly larger operational baseline than the previous year.
As trial pressures continue to grow, FutureMeds is directing its expanded capacity toward absorbing market demand, stabilising recruitment timelines, and ensuring that European site infrastructure remains a competitive asset for global drug development.
About The Sunday Times 100
The Sunday Times' fifth annual ranking, published online on Friday 5 June 2026, recognises Britain's 100 fastest-growing private companies, excluding those which sell their own technology.
The combined sales of this year’s top 100 companies reached £4 billion, up £600 million compared with the same table last year.
These businesses have created 8,900 jobs over the past three years and plan to add around 4,200 more in the next 12 months.
The Sunday Times 100 is sponsored by Barclays Private Bank.
To qualify for the list, businesses must be UK-registered, independent, unquoted, and have generated at least £5 million in sales in the latest year, with profits and no sales declines in the comparative periods.
Comments